This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB05137/identifier/chemspider/
n6http://linked.opendata.cz/resource/drugbank/drug/DB05137/identifier/chebi/
n14http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB05137/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n5http://linked.opendata.cz/resource/drugbank/drug/DB05137/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/drugbank/drug/DB05137/identifier/pubchem-compound/
owlhttp://www.w3.org/2002/07/owl#
n7http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05137/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB05137/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://linked.opendata.cz/resource/drugbank/drug/DB05137/identifier/drugbank/

Statements

Subject Item
n2:DB05137
rdf:type
n7:Drug
n7:description
An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
n7:generalReferences
# Miller DK, Lever JR, Rodvelt KR, Baskett JA, Will MJ, Kracke GR: Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend. 2007 Jul 10;89(2-3):282-91. Epub 2007 Mar 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17368966 # Wu J, Liu Q, Yu K, Hu J, Kuo YP, Segerberg M, St John PA, Lukas RJ: Roles of nicotinic acetylcholine receptor beta subunits in function of human alpha4-containing nicotinic receptors. J Physiol. 2006 Oct 1;576(Pt 1):103-18. Epub 2006 Jul 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16825297
n7:group
investigational
n7:indication
Investigated for use/treatment in addictions.
owl:sameAs
n14:DB05137
dcterms:title
Lobeline
adms:identifier
n4:DB05137 n5:C07475 n6:48723 n8:91814 n11:10232144 n12:Lobeline n15:D02364 n16:101616
n7:mechanismOfAction
Lobeline inhibits nicotine-evoked dopamine release and [3H]nicotine binding, thus acting as a potent antagonist at both alpha3beta2(*) and alpha4beta2(*) neuronal nicotinic receptor subtypes. However, lobeline does not release dopamine from its presynaptic terminal, but appears to induce the metabolism of dopamine intraneuronally. Reevaluation of the mechanism by which lobeline alters dopamine function reveals that its primary mechanism is inhibition of dopamine uptake and promotion of dopamine release from the storage vesicles within the presynaptic terminal, via an interaction with the tetrabenazine-binding site on the vesicular monoamine transporter (VMAT2). Thus, lobeline appears to perturb the fundamental mechanisms of dopamine storage and release. Based on its neurochemical mechanism, the ability of lobeline to functionally antagonize the neurochemical and behavioral effects of the psychostimulants amphetamine and methamphetamine was examined. Lobeline was found to inhibit the amphetamine-induced release of dopamine in vitro, and amphetamine-induced hyperactivity, drug discrimination, and self-administration.
n7:IUPAC-Name
n9:271B6496-363D-11E5-9242-09173F13E4C5
n7:InChI
n9:271B649C-363D-11E5-9242-09173F13E4C5
n7:Molecular-Formula
n9:271B649B-363D-11E5-9242-09173F13E4C5
n7:Molecular-Weight
n9:271B6498-363D-11E5-9242-09173F13E4C5
n7:Monoisotopic-Weight
n9:271B6499-363D-11E5-9242-09173F13E4C5
n7:SMILES
n9:271B649A-363D-11E5-9242-09173F13E4C5
n7:Water-Solubility
n9:271B6494-363D-11E5-9242-09173F13E4C5
n7:logP
n9:271B6495-363D-11E5-9242-09173F13E4C5 n9:271B6492-363D-11E5-9242-09173F13E4C5
n7:logS
n9:271B6493-363D-11E5-9242-09173F13E4C5
n7:H-Bond-Acceptor-Count
n9:271B64A2-363D-11E5-9242-09173F13E4C5
n7:H-Bond-Donor-Count
n9:271B64A3-363D-11E5-9242-09173F13E4C5
n7:InChIKey
n9:271B649D-363D-11E5-9242-09173F13E4C5
n7:Polar-Surface-Area--PSA-
n9:271B649E-363D-11E5-9242-09173F13E4C5
n7:Polarizability
n9:271B64A0-363D-11E5-9242-09173F13E4C5
n7:Refractivity
n9:271B649F-363D-11E5-9242-09173F13E4C5
n7:Rotatable-Bond-Count
n9:271B64A1-363D-11E5-9242-09173F13E4C5
n7:casRegistryNumber
90-69-7
n7:Bioavailability
n9:271B64A8-363D-11E5-9242-09173F13E4C5
n7:Ghose-Filter
n9:271B64AA-363D-11E5-9242-09173F13E4C5
n7:MDDR-Like-Rule
n9:271B64AB-363D-11E5-9242-09173F13E4C5
n7:Melting-Point
n9:271B64AC-363D-11E5-9242-09173F13E4C5
n7:Number-of-Rings
n9:271B64A7-363D-11E5-9242-09173F13E4C5
n7:Physiological-Charge
n9:271B64A6-363D-11E5-9242-09173F13E4C5
n7:Rule-of-Five
n9:271B64A9-363D-11E5-9242-09173F13E4C5
n7:Traditional-IUPAC-Name
n9:271B6497-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-acidic-
n9:271B64A4-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-basic-
n9:271B64A5-363D-11E5-9242-09173F13E4C5